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HTLV-1 infection of humanized NOG mice has been
demonstrated to recapitulate the development of ATL-like
symptoms within several months of infection. Infected
human T-cells in these mice start to proliferate vigorously
in a couple weeks after infection and the mice die of ALT-
like lymphoproliferative disorder. Thus, this mouse model
should provide a potent tool to analyze the in vivo effect
of various candidates for ATL treatment.
Treatment of ATL with the combination of anti-viral
agents, zidovudine (AZT) and interferon-alpha (IFN), has
been reported to be highly effective, especially to indolent
type, but the mechanism of action is totally unknown.
We, therefore, examined the efficacy and the in vivo
mechanism of AZT/IFN treatment in the humanized
mouse system.
HTLV-1 infected humanized mice were inoculated daily
with AZT and IFN from two to four weeks post infection
and the number of infected cells and proviral loads (PVL)
were analyzed. Treatment with either AZT or IFN alone
attenuated the onset of lymphoproliferative disorder,
whereas the combined treatment suppressed the growth
of infected T-cells in PBL almost completely and the PVL
remained low throughout lifetime. The suppressive effect
is infected-cell specific because the number of uninfected
human lymphocytes in PBL stayed constant on the admin-
istration of drugs.
It is suggested that infected cells expressing higher level
of viral gene, most provably Tax, should have been selec-
tively eliminated, since a similar suppressive effect has been
obtained in HTLV-1 infected humanized mice treated with
an Hsp90 inhibitor, 17-DMAG, which enhances the degra-
dation of Tax.
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